Eden Biodesign, a globally-integrated provider of biopharmaceutical process development, cGMP manufacturing and consultancy services, today announced it has been selected by Biotecnol SA to manufacture Cardiotrophin-1 for potential use in certain liver indications.
Eden Biodesign will generate the master cell bank and provide cGMP manufacture of drug substance for use in Phase I clinical trials. The manufacture of Cardiotrophin-1 will be undertaken in Eden Biodesign’s cGMP manufacturing suites at its licensed facilities located in Liverpool, UK.
Crawford Brown, PhD, Chief Executive Officer, Eden Biodesign commented: “We are delighted to be able to add Biotecnol to the wide range of established global pharmaceutical and biotechnology companies that have recognized Eden Biodesign’s expertise and long experience in the development and cGMP production of biopharmaceuticals derived from all major production platforms,” said Crawford Brown, PhD, chief executive officer for Eden Biodesign. The contract signifies Eden Biodesign’s continued strong growth in the marketplace and we are particularly pleased to be working on such an important product for treatment of serious hepatic conditions.”